Efficacy and safety in Tania, a randomised phase III trial of continued or reintroduced bevacizumab (bev) after 1st-line bev for HER2- negative locally recurrent/metastacic breast cancer (LR/MBC)

Authors :: Von Minckwitz, G
Puglisi, F
Cortes, J
Vrdoljak, E
Marschner, N
Zielinski, C
Villanueva CB
Publication Year :: 2014
Abstract: Efficacy and safety in Tania, a randomised phase III trial of continued or reintroduced bevacizumab (bev) after 1st-line bev for HER2-negative locally recurrent/metastacic breast cancer (LR/MBC)

Subjects :: skin and connective tissue diseases
neoplasms
breast cancer
metastatic

Tools